Shots:
- BMS reported topline P-III (SCOUT-HCM) trial data evaluating Camzyos (mavacamten) in 44 adolescents (12 to <18yrs.) with symptomatic oHCM, comprising a 28wk. PBO-controlled phase, an ongoing 28wk. active-treatment phase, & a 144wk. open-label LTE
- Trial met its 1EP, showing reduced Valsalva LVOT gradient at Wk. 28, & achieved statistical significance across multiple 2EPs, incl. those for clinically meaningful aspects of the disease; data to be presented in future & discussed with global regulators
- Camzyos is a selective, reversible allosteric cardiac myosin inhibitor that addresses HCM pathophysiology by reducing dynamic LVOT obstruction & improving cardiac filling pressures in pts with oHCM
Ref: Businesswire  | Image: BMS | Press Release
Related News: Harbour BioMed and BMS Collaborate in ~$1.1B Deal to Advance Next-Generation Multi-Specific Antibodies
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
